In the published article, there was an error in the author list, and author Daniel Gil-Alós was erroneously excluded. The corrected author list appears below.
Ana Jiménez-Ubieto 1*†, Alejandro Martín-Muñoz 1,2†, María Poza 1, Sara Dorado 2,3, Almudena García-Ortiz 1, Enrique Revilla 4, Pilar Sarandeses 5, Yanira Ruiz-Heredia 1,2, Tycho Baumann 1, Antonia Rodríguez 1, María Calbacho 1, Pilar Martínez Sánchez 1, José María Sánchez Pina 1, Alejandro Martín García-Sancho 6, Gloria Figaredo 1, Daniel Gil-Alós 1, Laura Rufián 1,2, Margarita Rodríguez 1,2, Laura Carneros 1, Carolina Martínez-Laperche 7, Mariana Bastos-Oreiro 7, Chongwu Wang 8, María-Teresa Cedena 1, Inmaculada Rapado 1, Paula de Toledo 3, Miguel Gallardo 1, Antonio Valeri 1, Rosa Ayala 1, Joaquín Martínez-López 1 and Santiago Barrio 1,2.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
follicular lymphoma, ctDNA (circulating tumor DNA), NGS (Next-Generation Sequencing), minimal residual disease, monitoring, PET/CT 18F-FDG, CAR T-cell therapy
Citation
Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Gil-Alós D, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena M-T, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J and Barrio S (2024) Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients. Front. Immunol. 14:1349296. doi: 10.3389/fimmu.2023.1349296
Received
04 December 2023
Accepted
21 December 2023
Published
10 January 2024
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
14 - 2023
Updates
Copyright
© 2024 Jiménez-Ubieto, Martín-Muñoz, Poza, Dorado, García-Ortiz, Revilla, Sarandeses, Ruiz-Heredia, Baumann, Rodríguez, Calbacho, Sánchez, Pina, García-Sancho, Figaredo, Gil-Alós, Rufián, Rodríguez, Carneros, Martínez-Laperche, Bastos-Oreiro, Wang, Cedena, Rapado, de Toledo, Gallardo, Valeri, Ayala, Martínez-López and Barrio.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ana Jiménez-Ubieto, anitiju@hotmail.com; Santiago Barrio, santiago_barrio@altumsequencing.com
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.